The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Open accessAbstract
The three design criteria of anticancer nanomedicines to improve anticancer efficacy and to reduce toxicity have been debated for decades: (1) Nanomedicines increase drug accumulation through enhanced permeability and retention (EPR) in tumors to improve anticancer efficacy. (2) Long systemic circulation of nanomedicines with high plasma concentration reduces reticuloendothelial system (RES) clearance and decreases drug accumulation in the normal organs to reduce toxicity, and to enhance the EPR effect. (3) A universal nanodelivery platform based on EPR and long systemic circulation can be developed to deliver different anticancer drugs. Although these criteria have repeatedly been confirmed in preclinical xenograft cancers, the majority of anticancer nanomedicines have failed to improve clinical efficacy, while the clinical efficacies/safety of successful nanomedicines are inconsistent with these design criteria. First, the debate over tumor EPR may have mixed two different questions and missed more clinically relevant comparisons for nanomedicines versus free drugs. When tumors are compared with normal tissues, tumor EPR has been confirmed in both mouse xenograft tumors and human cancers. However, nanomedicines may not enhance drug accumulation in human tumors compared with free drugs, despite outstanding improvement in preclinical cancers. Heterogeneity of enhanced permeability and retention in human cancers occurs for small/large molecules and nanomedicines, which cannot fully explain the poor translation of nanomedicines' efficacy from preclinical cancer models to cancer patients. Second, long-circulation nanomedicine should not be used as a universal design criterion because it does not further improve tumor accumulation by tumor EPR in human patients nor universally reduce distribution in normal organs. In contrast, nanomedicines change the drug tissue distribution to alter anticancer efficacy/safety. Third, a universal nanodelivery platform that uses the same design criteria for different drugs is not feasible. Rather, drug-specific nanodelivery systems are required to overcome the intrinsic shortcomings of delivered drugs, which are determined by the physicochemical, pharmacokinetic, and pharmacodynamic properties of the delivered drugs and nanocarriers to improve their efficacy/safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Mechanism of hard-nanomaterial clearance by the liver
Tsoi, K. M., MacParland, S. A., Ma, X.-Z., Spetzler, V. N., Echeverri, J., Ouyang, B., Fadel, S. M., Sykes, E. A., Goldaracena, N., Kaths, J. M., et al. (2016) · Nature Materials · doi:10.1038/nmat4718 · Cited by 1,010
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Cesarman, E., Damania, B., Krown, S. E., Martin, J., Bower, M., & Whitby, D. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0060-9 · Cited by 697
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
Investigating the optimal size of anticancer nanomedicine
Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., Yao, C., Zhou, Q., Kwon, M., Hartman, J. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411499111 · Cited by 654
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
Flatters, S. J. L., & Bennett, G. J. (2004) · Pain · doi:10.1016/j.pain.2004.01.029 · Cited by 576
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
The battle of “nano” paclitaxel
Sofias, A. M., Dunne, M., Storm, G., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.02.003 · Cited by 401
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2548 · Cited by 286
Effect of removing Kupffer cells on nanoparticle tumor delivery
Tavares, A. J., Poon, W., Zhang, Y.-N., Dai, Q., Besla, R., Ding, D., Ouyang, B., Li, A., Chen, J., Zheng, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713390114 · Cited by 286
Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)
Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl477 · Cited by 265
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Yaseen, A. D. B., Kawaguchi, T., & Jankowiak, R. (2009) · International Journal of Nanomanufacturing · doi:10.1504/ijnm.2009.028116 · Cited by 218
Shitara, K., Takashima, A., Fujitani, K., Koeda, K., Hara, H., Nakayama, N., Hironaka, S., Nishikawa, K., Makari, Y., Amagai, K., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30219-9 · Cited by 217
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
High throughput toxicity screening and intracellular detection of nanomaterials
Collins, A. R., Annangi, B., Rubio, L., Marcos, R., Dorn, M., Merker, C., Estrela‐Lopis, I., Cimpan, M. R., Ibrahim, M., Cimpan, E., et al. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1413 · Cited by 207
EPR-effect: Utilizing size-dependent Nanoparticle Delivery to Solid Tumors
Stylianopoulos, T. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.8 · Cited by 197
Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., & Helidonis, E. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3512 · Cited by 191
Vail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., & Working, P. K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.002 · Cited by 187
Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., & Karkavitsas, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1459 · Cited by 186
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Batist, G., Barton, J., Chaikin, P., Swenson, C., & Welles, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1739 · Cited by 179
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar-Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 162
The beginning of the end of the nanomedicine hype
Park, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.044 · Cited by 158
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 155
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 151
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.289 · Cited by 133
Chen, N., Brachmann, C. B., Liu, X., Pierce, D. W., Dey, J., Kerwin, W. S., Li, Y., Zhou, S. Y., Hou, S., Carleton, M. O., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2833-5 · Cited by 130
Self-citationMifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 128
Evaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126
Chen, N., Li, Y., Ye, Y., Palmisano, M., Chopra, R., & Zhou, S. Y. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.304 · Cited by 123
Self-citationHuang, S. K., Martin, F. J., Jay, G. D., Vogel, J. C., Papahadjopoulos, D., & Friend, D. S. (1993) · PubMed · Cited by 123
Koukouraki, A. M. I. K. S. (2000) · Acta Oncologica · doi:10.1080/028418600430789 · Cited by 122
Yuan, H., Guo, H., Luan, X., He, M., Li, F., Burnett, J., Truchan, N. A., & Sun, D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01221 · Cited by 120
Self-citationStylianopoulos, T., Economides, A. E., Baish, J. W., Fukumura, D., & Jain, R. K. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1276-9 · Cited by 99
Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
横道, 憲., Nagasawa, T., Coler-Reilly, A. L. G., Suzuki, H., Kubota, Y., Yoshioka, R., Tozawa, A., Suzuki, N., & Yamaguchi, Y. (2013) · Human Cell · doi:10.1007/s13577-012-0057-0 · Cited by 98
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-1022-3 · Cited by 96
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Giordano, G., Pancione, M., Olivieri, N., Parcesepe, P., Velocci, M., Raimo, T. D., Coppola, L., Toffoli, G., & D'Andrea, M. R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i32.5875 · Cited by 93
Herrera, D. A., Ashai, N., Perez-Soler, R., & Cheng, H. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1546290 · Cited by 75
Cancer nanomedicines: closing the translational gap
Gabizón, A., Bradbury, M. S., Prabhakar, U., Zamboni, W. C., Libutti, S. K., & Grodzinski, P. A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61457-4 · Cited by 73
Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
Pisano, C., Cecere, S. C., Napoli, M. D., Cavaliere, C., Tambaro, R., Facchini, G., Scaffa, C., Losito, S., Pizzolorusso, A., & Pignata, S. (2013) · Journal of Drug Delivery · doi:10.1155/2013/898146 · Cited by 70
Luo, R., Li, Y., He, M., Zhang, H., Yuan, H., Johnson, M. T., Palmisano, M., Zhou, S. Y., & Sun, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.002 · Cited by 69
Self-citationHamilton, E. P., Kimmick, G. G., Hopkins, J. O., Marcom, P. K., Rocha, G., Welch, R. A., Broadwater, G., & Blackwell, K. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.003 · Cited by 62
Nanoparticle transport pathways into tumors
Moghimi, S. M., & Simberg, D. (2018) · Journal of Nanoparticle Research · doi:10.1007/s11051-018-4273-8 · Cited by 62
Jain, M. M., Gupte, S. U., Patil, S. G., Pathak, A. B., Deshmukh, C. D., Bhatt, N., Haritha, C., Babu, G., Bondarde, S. A., Digumarti, R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3736-9 · Cited by 57
Arrieta, O. G., Medina, L. A., Estrada-Lobato, E., Ramírez-Tirado, L.-A., Mendoza-García, V. O., & de la Garza-Salazar, J. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2477-x · Cited by 52
Carnevale, J. C., & Ko, A. H. (2015) · Future Oncology · doi:10.2217/fon.15.333 · Cited by 51
Li, Y., Chen, N., Palmisano, M., & Zhou, S. Y. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00026 · Cited by 47
Self-citationArrieta, O. G., Medina, L. A., Estrada-Lobato, E., Hernández‐Pedro, N., Villanueva‐Rodriguez, G. M., Martínez-Barrera, L. M., Macedo, E. O., López‐Rodríguez, V., Motola‐Kuba, D., & Corona-Cruz, J. F. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.44 · Cited by 46
Hoy, S. M. (2014) · Drugs · doi:10.1007/s40265-014-0291-8 · Cited by 44
Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer
Yamaguchi, T., Fushida, S., Yamamoto, Y., Tsukada, T., Kinoshita, J., Oyama, K., Miyashita, T., Tajima, H., Ninomiya, I., Munesue, S., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5586 · Cited by 43
Kavanagh, J. J., Levenback, C. F., Ramirez, P. T., Wolf, J. L., Moore, C. L., Jones, M., Meng, L., Brown, G. L., & Bast, R. C. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-9 · Cited by 28
Personal perspectives and concerns over the so-called nanomedicine
Yang, V. C.-M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.021 · Cited by 23
Li, F., Zhang, H., He, M., Liao, J., Chen, N., Li, Y., Zhou, S. Y., Palmisano, M., Yu, A., Pai, M. P., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00527 · Cited by 21
Self-citationNCI Centers of Cancer Nanotechnology Excellence (CCNEs) – A full story to set the record straight
Grodzinski, P. A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.016 · Cited by 19
Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis
Jahn, F., Jordan, K., Behlendorf, T., Globig, C., Schmoll, H., Müller‐Tidow, C., & Jordan, B. (2015) · Oncology · doi:10.1159/000380913 · Cited by 18
Henderson, L. A., & Shankar, L. K. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9995-x · Cited by 10
Saeki, T., Mukai, H., Ro, J., Yc, L., Fujiwara, Y., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S.-B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx365.013 · Cited by 8
Romeo, C., Joly, F., Ray-Coquard, I. L., Kouri, C. E., Mercier-Blas, A., Berton-Rigaud, D., Kalbacher, E., Cojocarasu, O., Fabbro, M., Cretin, J., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.043 · Cited by 5
Cited by
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Self-citationMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
The mechanisms of nanoparticle delivery to solid tumours
Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00154-9 · Cited by 257
Challenges and Opportunities of Nanomedicines in Clinical Translation
Zheng, C., Li, M., & Ding, J. (2021) · BIO Integration · doi:10.15212/bioi-2021-0016 · Cited by 194
Towards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
Metadata
- Authors
- Sun, D., Zhou, S., & Gao, W.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-10-06
- Volume
- 14
- Issue
- 10
- Pages
- 12281-12290
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3091453524
- Cited by
- 263
- References
- 100
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.